An in vitro model for disease-specific immunotherapy in myasthenia gravis using soluble MHC class II bound to AChR-derived peptide.
Nicolle
M W
MW
Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, United Kingdom.
Vincent
A
A
Sharma
S
S
Nag
B
B
Willcox
N
N
Newsom-Davis
J
J
D006684:HLA-DR Antigens / Q000737:chemistry*; D007167:Immunotherapy; D066298:In Vitro Techniques; D008213:Lymphocyte Activation; D009157:Myasthenia Gravis / Q000628:therapy*; D011978:Receptors, Nicotinic / Q000737:chemistry* / Q000276:immunology; D012995:Solubility; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology*
D006684:HLA-DR Antigens; D011978:Receptors, Nicotinic